Koers Willow Biosciences Inc Canadian Securities Exchange
Aandelen
CA97111B1076
Farmaceutische producten
Omzet 2022 | 821K 600K 562K | Omzet 2023 | 1,17 mln. 857K 802K | Marktkapitalisatie | 12,42 mln. 9,08 mln. 8,5 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -14 mln. -10,23 mln. -9,58 mln. | Nettowinst (verlies) 2023 | -13 mln. -9,5 mln. -8,89 mln. | EV/omzet 2022 | -0,95 x |
Nettoliquiditeiten 2022 | 15,01 mln. 10,97 mln. 10,27 mln. | Nettoliquiditeiten 2023 | 1,63 mln. 1,19 mln. 1,11 mln. | EV/omzet 2023 | 9,21 x |
K/w-verhouding 2022 |
-0,96
x | K/w-verhouding 2023 |
-0,95
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 72,66% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chris Savile
CEO | Chief Executive Officer | - | 12-04-19 |
Travis Doupe
DFI | Director of Finance/CFO | - | 12-04-19 |
Trish Choudhary
CTO | Chief Tech/Sci/R&D Officer | - | 01-04-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jim Lalonde
CHM | Chairman | 63 | 21-02-23 |
Donald Archibald
BRD | Director/Board Member | 63 | 12-04-19 |
Director/Board Member | 51 | 12-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-4,66% | 86,13 mld. | |
+1,32% | 39,82 mld. | |
-19,27% | 30,42 mld. | |
+57,86% | 25,23 mld. | |
-16,09% | 15,35 mld. | |
-9,14% | 11,95 mld. | |
-17,69% | 11,6 mld. | |
-43,00% | 11,51 mld. | |
+5,24% | 8,71 mld. |